TABLE 3.
Showing prevalence, clinical presentation and treatment of systemic mastocytosis and papillary thyroid cancer. 1 , 2 , 3
| Prevalence | Age | Male/Female | Clinical presentation | Treatment | Prognosis | |
|---|---|---|---|---|---|---|
| Systemic mastocytosis | 1:10,000‐20,000 | No specific age cutoff (median age for indolent disease: 49 years old) | Equal ratio | Pruritus, flushing, abdominal cramping/diarrhea, nausea/vomiting, headache | Avoidance of triggers, treatment of comorbidities, in aggressive cases consider KIT‐inhibitors, Imatinib, Interferon alpha | Few months to normal life expectancy |
| Papillary thyroid cancer | 14.9:100,000 | Average age 48 at diagnosis | 75% female | Painless thyroid mass, cervical lymphadenopathy, voice changes | Surgical removal of thyroid, radioactive iodine administration | 5‐year survival rate 98% approximately |